Introduction
Ante-natal thromboembolism is an important cause of maternal morbidity and mortality. Selfadministered subcutaneous heparin has been recommended for use during pregnancy and for the first 6 weeks of lactation, in high-risk patients (Spearing et al., 1978) . However, pregnancy may increase the risk of skeletal demineralization from prolonged heparin therapy (Wise and Hall, 1980 The pain rapidly abated after stopping the heparin. After 4 weeks in a plaster jacket, an iliac crest bone biopsy was taken. Histology revealed moderate osteoporosis with excess osteoid, characteristic of bone remodelling.
Discussion
There are no previous reports in the English literature of heparin-induced osteoporosis from a dose as low as 10,000 units daily, in the absence of other osteopenic agents, such as adrenal corticosteroids. In addition to the low dose, the duration of treatment (36 weeks) in our case was also relatively short. The treatment period in other cases ranges from 9 weeks in a 20-year-old pregnant patient (Aarskog; Aksnes and Lehmann, 1980) to 5 years in a 53-year-old man with ischaemic heart disease (Griffith et aL, 1965) . Susceptibility to the skeletal effects of heparin varies between individuals.
The mechanism by which heparin causes osteo-porosis is unknown. As heparin is a potent inhibitor of a variety of enzymatic reactions, it may exert its effect via enzyme systems involved with bone and mineral metabolism (Avioli, 1975) such as collagen synthesis and maturation, vitamin D activation, and parathyroid induced increases in skeletal cyclic adenosine monophosphate. The apparent sensitivity in our patient may be due to her pregnant state. During pregnancy and lactation there is an increased demand on the mother for calcium. It is thought that the maternal skeleton is protected from decalcification by a rise in production of calcitonin throughout this period (Stevenson, Hillyard and Maclntyre, 1979) . Individuals, who have low levels of calcitonin during pregnancy, may be predisposed to skeletal dimineralization. In such a patient, heparin administration may further aggravate the mineral loss. Thus overt heparin osteoporosis may appear in a pregnant patient, where the dose of heparin used is much less than the doses incriminated in non-pregnant cases. Heparin osteoporosis is rare, but its effects in a young mother may be devastating. 
